Mustang Bio
MBIOMustang Bio is a clinical-stage biopharmaceutical company dedicated to developing next-generation therapies for difficult-to-treat cancers, with a primary focus on solid tumors.
Earnings
Next report
Nov 18, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Mustang Bio is a clinical-stage biopharmaceutical company dedicated to developing next-generation therapies for difficult-to-treat cancers, with a primary focus on solid tumors. The company operates by licensing medical breakthroughs from academic institutions and funding their clinical development toward commercialization or out-licensing. Their core value proposition lies in the integration of CAR T-cell therapies with oncolytic viruses to overcome the challenges of treating malignant brain tumors.
A clinical-stage innovator focused on niche orphan drug designations for glioblastoma and high-grade astrocytoma.
FAQ
- What is Mustang Bio's market cap?
- Mustang Bio (MBIO) has a market capitalization of $3.8M and trades on NASDAQ.
- Who are Mustang Bio's competitors?
- Mustang Bio's key competitors include Gilead Sciences, Bristol-Myers Squibb, Actinium Pharmaceuticals, Inc, and others. These companies compete in similar markets and product categories.
- Who does Mustang Bio partner with?
- Mustang Bio's notable partners include City of Hope National Medical Center, Nationwide Children’s Hospital, University of Alabama at Birmingham.
- Where is Mustang Bio headquartered?
- Mustang Bio is headquartered in United States of America and employs approximately 80 people. It has been publicly traded since 2017.